CNS Pharmaceuticals (CNSP) vs Immuron (IMRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immuron is the larger company by market cap ($9.0 million vs $7.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSP | IMRN |
|---|---|---|
| Share price | $5.35 | $1.11 |
| Market cap | $7.82M | $8.96M |
| 1-day change | -1.47% | +1.83% |
| EPS (TTM) | $-17.90 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.54 | $2.39 |
| 52-week low | $1.90 | $0.677 |
| Distance from 52-week high | -49.24% | -53.56% |
| Analyst consensus | none | none |
| Avg. price target upside | +86.92% | +250.45% |
| Average volume | 6.40K | 2.06M |
| Shares outstanding | 1.46M | 8.07M |
| Employees | 8 | 7 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CNS Pharmaceuticals
CNSP stock →CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.
Healthcare · Biotechnology · 8 employees
About Immuron
IMRN stock →Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.
Healthcare · Biotechnology · 7 employees
CNSP vs IMRN FAQ
Which is bigger, CNS Pharmaceuticals or Immuron?
Immuron (IMRN) is larger, with a market capitalization of $8.96M compared with $7.82M for CNS Pharmaceuticals (CNSP).
Are CNS Pharmaceuticals and Immuron in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.